Capitalizing on Opportunities in Cord Blood Industry Growth –

Overview: Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations. Deeper analysis reveals that of existing cord blood banks, most fall into one of two “camps,” either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (17% or more per annum).

This finding begs the questions:

•What factors are causing a substantial number of new cord blood banks to open up business? Is it the result of a profit opportunity, an effect of advances in therapeutic applications, a social response to more parents being aware of the opportunity to store cord stem cells at birth, or are other factors driving the activity?

•What will be the effect of these new entrants to the cord blood banking industry for existing competitors?

•Perhaps most critically, what are the differences among the cord blood banks that are experiencing flat-line growth, versus those that have substantively built revenue over the past 12 months?
In BioInformant’s initial version of this report, “Choices in Cord Blood Banking – Factors Influencing Parental Decision-Making,” launched April 2009, an survey of 1,200 expectant parents was used to provide a roadmap for how cord blood banks can best communicate and market their services to potential clients. The top-selling report explored the specific reasons that parents elect to store cord blood and what factors influence their decision-making in choosing a specific bank. (Click here to read the Executive Summary for the original version of the report.)

This expanded and updated version includes from the original report, as well as supplemental analysis of factors that have produced double-digit industry growth over the past year. It provides guidance on how to break through flat-line growth to become a fast-growing competitor within the cord blood industry.

Executive Summary

Overview: Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.”
Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the Cord Blood Banking Industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents answered the detailed survey. The survey initially focused on U.S. respondents, but due to international interest was expanded to include respondents from Canada, Mexico, South America, Europe, Asia, Australia, and other regions as well.

Key findings of the report includes:

•Rates of awareness by gender, income, geographic location, and education
•Sources through which expectant parents learn of cord blood preservation
•Factors influencing private vs. public storage of cord blood
•Price sensitivity and quality expectations
•Approaches for communicating with expectant parents
•Key factors influencing the decision to store cord blood
•Parental responsiveness to health statistics
•Trends in cord blood banking
•Competitive analysis of the cord blood banking industry

http://www.aarkstore.com/reports/Capitalizing-on-Opportunities-in-Cord-Blood-Industry-Growth-32359.html

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors – Aarkstore Enterprise

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma’s bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals.

Furthermore, recent increases in internal Biopharma consolidation are an indicator of the ability of well-established Biopharma companies to effectively compete against traditional big Pharma.

‘Evolving Trends in Biopharmaceutical Licensing’ is a report provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. The future prospects of the industry are assessed and the potential impact of political/regulatory factors upon licensing and alliances is identified. This report also investigates the influence of the recent upsurge in M&A activity and provides recommendations on the strategies that can sustain future growth.

Key Findings

• Several top-ranked Biopharma companies have matched the consistent sales growth of major traditional pharma companies. A key component of this success has been the increasing reliance of big Pharma to improve R&D productivity and rejuvenate sales of marketed portfolios through licensing and partnership deals.
• Big Pharma has been acquiring Biopharma companies at an increasing rate, resulting in this becoming the fastest-growing M&A sector in 2008 with deal values up 87%. Intense competition and financial uncertainty has also prompted a surge in biopharma consolidation, with 52 biopharma/biopharma deals in 2007.
• Considerable potential for Biopharma licensing deals still exists, particularly within the OAD class of drugs and non-invasive insulin drug delivery technologies.
• The total deal size of early-stage alliances with biopharma has increased six-fold, with total deal values in 2007 estimated at $18bn. This has been driven by the relatively lower costs of discovery and lead development, despite the higher risk of failure.
• Co-development/co-promotion deals accounted for 30% of licensing deals over 2006-07. Licensing deals will continue to become more complex due to biopharma’s desire to remain involved in their product lifecycle beyond the stages of discovery and development

Use this report to…

• Examine the licensing landscape of the biopharma industry with this report’s analysis of Biopharma and Pharma licensing and alliance activity and an examination of specific approaches utilized by both sectors.
• Discover the drivers and challenges facing Biopharma licensing, understand how Biopharma companies are preparing to exploit new opportunities and assess deal-making trends across clinical trials phases and key therapeutic areas.
• Evaluate the strategies of leading companies involved in biopharmaceutical licensing with this report’s analysis of deal activities amongst leading players and identify the changing dynamics of Biopharma/Pharma partnerships.
• Assess the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth.

Explore issues including…

• Biopharmas reduced reliance on Pharma. Biopharma is sustaining its efforts to increase its role outside of product development/discovery to become actively engaged in the future of their products. As such, it is becoming increasingly difficult to differentiate big Pharma from major Biopharma companies.
• Optimizing revenue potential. Biopharma are increasingly targeting high value therapy areas, such as oncology and inflammatory disease, bringing them into direct competition with major Pharma.
• Future competitive strategies. With licensing deals increasing in value and complexity, Biopharma companies are looking to increase their involvement by forming long-term, partnership-based relationships. This active engagement in licensing deals will typically involve the negotiation of equity investment and the co-promotion and co-marketing of a drug that allows Biopharma to generate additional downstream revenues.
• Drug development potential. The emergence of several new Biopharma companies with innovative technology platforms has created immense potential for intra-Biopharma licensing trends to continue developing novel drugs that can successfully differentiate themselves within the marketplace.

Discover…

• How will the increasing competition for attractive Biopharma licensing candidates affect deal terms and values?
• How can Biopharma companies improve their licensing strategies to ensure future growth?
• What have been the major trends in licensing agreements between Biopharma and Pharma over 2001-08?
• Which strategies have Biopharma used to reduce their reliance on Pharma?
• How has the value, volume and competition for Biopharma licensing deals changed over 2001-08?
• What have been the strategies of successful Biopharma and Pharma deal-makers?
• Why are Biopharma and Pharma increasingly adopting M&A strategies instead of entering into licensing agreements?

For more information, kindly visit :
http://www.aarkstore.com/reports/Evolving-Trends-in-Biopharmaceutical-Licensing-Deal-assessments-drivers-and-resistors-13949.html

Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011. With some of the earliest biopharmaceuticals having already lost patent protection, the originators of biopharmaceutical products are facing intense competition from generics developers. In response, originators are resorting to a range of defensive tactics, including the reformulation of existing products to improve efficacy, the implementation of more efficient delivery systems and the pursuit of high-level intellectual property (IP) battles.

‘Negotiating the Emerging Biosimilars Landscape’ is a new report published by Business Insights that examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. The key factors affecting market access within the biosimilars market are assessed and the latest issues surrounding bioequivalence are examined. This report also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

Key Findings

European Union guidelines have been prepared which authorise the use of specific therapeutic biopharmaceutical medicines as biosimilars. However, despite the range of current European guidelines produced by the EMEA, many European governments have issued laws prohibiting the automatic substitution of original products.

No approval pathway for biosimilars (FOB) exists in the USA, and one is unlikely to exist before 2010. A complex range of Acts and Bills have failed to resolve a number of outstanding legal and regulatory issues.

India’s biopharmaceutical industry is projected to grow to almost $5 billion by the end of 2010, representing annual growth in excess of 30%. However, despite WTO membership and recent advances in compliance with international regulatory/intellectual property laws, there remains no formal regulatory framework for biosimilars in India or China.

Health Canada has not yet publicly announced a legal or regulatory framework for biosimilar approval, and no legal framework for biosimilars currently exists in Japan. New regulatory frameworks and biosimilar guidelines are currently under development in both countries.

Use this report to…

• Identify and respond to the challenges and threats posed by the emergence of the biosimilars industry with this report’s examination of key trends and strategic approaches used by the biopharmaceutical industry to protect market share and intellectual property.
• Examine details of expired patents or impending patent expiries for first-gen biopharmaceuticals derived from recombinant DNA such as interferons, human insulin and insulin analogs, monoclonal antibodies (Mab) growth hormone and epoietins.
• Evaluate the legislative and regulatory requirements for biosimilars across key geographic regions including Europe, the US, Japan, Australia, Canada as well as the strategically important emerging markets of China and India.
• Assess the factors affecting biosimilar market access with this report’s analysis of the drivers and restraints to biosimilar approval, use and uptake, in addition to an investigation of the problems associated with determining bioequivalence.

Explore issues including…

Impending patent expiries. The critical challenge facing the biopharmaceutical industry is the expiry or pending expiry of patents for first generation biopharmaceuticals derived from recombinant DNA such as interferons, growth hormone and epoietins.

Defensive strategies. As part of efforts to protect the market share of products with impending patent expiries, originator biopharmaceutical companies have begun to protect intellectual property and engage in strategic alliances, joint ventures and mergers between themselves and major pharma companies.

Geographical disparities in biosimilar legislation. Different geographic regions have varying legislative approaches to the regulation and/or approval of biosimilars. Such discrepancies often lead to misunderstandings and can result in complexity and complication during the approval process.

Discover…

• Which biopharmaceutical companies are at risk from product patent expires?
• What is the status of the analytical techniques used for determining bioequivalence?
• What tactics prove most effective for originator biopharmaceutical companies who wish to protect their market position?
• What effect the market entry of second generation biopharmaceuticals by originator companies have on the biosimilars market?
• What are the growth drivers and restraints of the biosimilars market?
• How are global healthcare costs influenced by biosimilar market entry prospects?
• What is the current legislative and regulatory status of biosimilars in Europe and the US?
• How will China and India influence the biopharmaceutical and biosimilars market in the future?

For more information, kindly visit :
http://www.aarkstore.com/reports/Negotiating-the-Emerging-Biosimilars-Landscape-Key-Developments-in-the-Regulatory-Environment-13944.html

Welcome to Aarkstore Market Research Aggregation

We specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether you’re looking for new product trends or competitive analysis of a new or existing market, Aarkstore.com has the best resource offerings and the expertise to make sure you get the right product every time. 
 
http://www.aarkstore.com

Top 200 Pharma Company Profiles By Aarkstore Enterprise

Key Findings & Highlights

- The report presents the business profile/major therapeutic segments, names of the directors, subsidiaries and agreement/alliances.
- The companies’ R&D facilities and financial highlights are given for the last five years (and updated till 2007-08 wherever information is available)
- Foreign investors will get primary information about major pharma companies in India with latest financials and other vital inputs.
- The report provides a ready reckoner which enables to understand the companies manufacturing,R&D and plant approvals

Reasons to Buy

- Access all the important information and analysis on the company in a single report
- Understand company’s overview, plant approvals,R&D etc
- Gain access to company’s adjusted five year financial data along with vital facts

For more information, kindly visit :
http://www.aarkstore.com/reports/Top-200-Pharma-Company-Profiles-12554.html

Biogenerics, The World Market: Biosimilars and Follow-On Biologics at a Crossroads

Worldwide interest in biogenerics or biosimilars is gaining momentum. Since Kalorama Information last visited the market for synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies four years ago, there has been much more worldwide involvement in the development of the biogeneric arena.

The biological drug market is at a crossroad. Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. This opens up the market currently worth $40 billion and growing at over 20% per year if the regulatory hurdles can be overcome.

Kalorama Information’s survey includes as part of its market analysis a breakdown of generic replacements for:

• Drugs with Active patents
• Drugs with Expired patents

with this geographic breakdown:

• World
• US
• non-US

In addition to market information, this report includes:

• Complete Overview
• Patent dates for Major Biopharmaceuticals
• Issues and Trends in the Industry
• Scientific Differences Between Biopharmaceuticals and Biogenerics
• Key Regulations Affecting this Market
• Company Profiles

As part of Kalorama Information’s trusted information gathering process, this report is the result of both primary and secondary research. In addition to exhaustive research, Key executives at biogeneric companies were consulted to uncover key trends and develop models.

For more information, please visit : http://www.aarkstore.com/reports/Biogenerics-The-World-Market-Biosimilars-and-Follow-On-Biologics-at-a-Crossroads-12931.html  Or email us at press@aarkstore.com or call +919272852585.